Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04664569
Recruiting Observational

National Bacterial Meningitis Study in Children and Newborns

NCT04664569 · tracked via the Priya Life Science France tracker
Sponsor
Association Clinique Thérapeutique Infantile du val de Marne
Phase
Observational
Started
2001-01-01
Last updated
2026-04-28

Condition(s) studied

MeningitisChildren, OnlyPneumococcal Conjugate VaccineMeningococcal VaccinesH. Influenzae VaccineNeonatal InfectionAntibiotic TreatmentCase Fatality Rate

Study summary

Bacterial meningitis is a major cause of morbidity and mortality in childhood. Antibiotic treatment recommendations are based on epidemiological and susceptibility data. The epidemiology of bacterialméningitis has changed in recent years, mainly owing to widespread use of different conjugate vaccines. The aim of this prospective national survey is to describe epidemiology of bacteria implicated in bacterial meningitis in children.

Eligibility

Sex
ALL
Min age
1 Day
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * clinical signs of meningitis, associated with positive cerebrospinal fluid (CSF) culture and/or positive CSF antigen testing (Escherichia coli K1, N. meningitidis serogroups B, A, C, Y and W-135, group B streptococci, Hib, or S. pneumoniae), and/or positive CSF polymerase chain reaction (PCR), and/or positive blood culture with CSF pleocytosis (\> 10 cells/µL). * purpura fulminans Exclusion Criteria: \-

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
ACTIV Créteil France Recruiting

More Association Clinique Thérapeutique Infantile du val de Marne trials in France

Pediatric and Ambulatory Research in Infectious Diseases Recruiting
National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns Recruiting
Pediatric Pertussis in Ambulatory Settings Recruiting
CommunautAry Pediatric bacteRial Infection in Intensive CarE Unit Recruiting
Bacteriological Evaluation of Children With Otorrhea Recruiting

Other trials for the same condition

Impact of a Multi-infusion Strategy in Neonatology on the Rate of Central Line-associated Bloodstream Infections Recruiting
National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns Recruiting
Pediatric Pertussis in Ambulatory Settings Recruiting
Nasopharyngeal Carriage of S. Pneumoniae Recruiting
Evolving Diagnostic Approaches to Undocumented Lymphocytic Meningitis and Meningoencephalitis Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04664569 on ClinicalTrials.gov ↗ ← All trials in France